| Literature DB >> 34707393 |
Ramón Pérez-Tanoira1,2, Lourdes Lledó García1, Miguel Torralba González de Suso3,4, Manuel Rodríguez Zapata4, Teresa Arroyo Serrano2, Consuelo Giménez Pardo1, María Isabel Rodríguez Pedrosa5, Mª Nuria Romero Badía5, Felipe Pérez-García1,2, Patricia González López5, Cristina Villaescusa García5, Juan Cuadros González1,2.
Abstract
PURPOSE: Seroprevalence against SARS-CoV-2 within university systems is poorly studied, making evidence-based discussions of educational system reopening difficult. Moreover, few studies evaluate how antibodies against SARS-CoV-2 are maintained over time. We assessed serological response against the SARS-CoV-2 virus among our university students and staff. PATIENTS AND METHODS: In this prospective cohort study, seroprevalence was determined in 705 randomly selected volunteers, members of the Faculty of Medicine and Health Sciences of the University of Alcalá, using a chemiluminescent Siemens' SARS-CoV-2 immunoassay for total antibodies. Positive samples were tested for IgG and IgM/IgA using VIRCLIA® MONOTEST (Vircell). A first analysis took place during June 2020, and in those testing positive, a determination of secondary outcomes was performed in November 2020.Entities:
Keywords: COVID-19; SARS-CoV-2; degree of health sciencies; seroprevalence; university
Year: 2021 PMID: 34707393 PMCID: PMC8544125 DOI: 10.2147/IJGM.S332803
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Serological Assay Results and Epidemiological Characteristics of 705 Study Participants from the Faculty of Medicine and Health Sciences of the University of Alcalá, Madrid, Spain
| Univariate Analysis | Multivariate Analysisa | |||||
|---|---|---|---|---|---|---|
| Variables | Groups | IgG/IgM + % | p | OR (95% CI) | p | OR (95% CI) |
| Gender | Male | 19.5 | 0.636 | 1.10 (0.33–1.67) | 0.348 | 1.28 (0.76–1.56) |
| Female (REF) | 18.0 | |||||
| Type of members of the UAH | FMHS (REF) | 17.2 | REF | 0.559 | REF | |
| TRS | 25.8 | 0.295 | 0.71 (0.37–1.35) | |||
| AO | 13.6 | 0.464 | 0.76 | 0.958 | 1.03 (0.41–2.59) | |
| Position at the UAH | Medicine(183) | 12.6 | 0.312 | REF | 0.486 | REF |
| TRS PASS(13) | 0.0 | NA | NA | NA | NA | |
| Nursery and Fis(26) | 38.5 | 0.908 | 1.08(0.31–3.734) | |||
| TRS Nursery(15) | 13.3 | 0.932 | 1.07(0.23–5.05) | 0.096 | 0.15 (0.017–1.395) | |
| TRS Fis(8) | 12.5 | 0.995 | 0.99(0.12–8.45) | 0.246 | 0.19(0.01–3.19) | |
| TRS Medicine(70) | 30.0 | 0.275 | 1.62(0.68–3.89) | |||
| AO(66) | 13.6 | 0.824 | 1.10(0.48–2.51) | 0.582 | 1.35(0.46–3.92) | |
| S PASS(85) | 18.0 | 0.179 | 1.61(0.80–3.24) | 0.215 | 1.79(0.71–4.51) | |
| Nursery UAH(98) | 20.6 | 0.078 | 1.81(0.94–3.49) | 0.613 | 1.22(0.57–2.64) | |
| Nursery Guada(76) | 21.3 | 0.077 | 1.89(0.93–3.82) | 0.169 | 1.75(0.79–3.90) | |
| Fisioterapy(65) | 18.5 | 0.244 | 1.58(0.73–3.38) | 0.201 | 1.73(0.75–4.0) | |
| Risk | High risk(377) | 22.1 | 0.86 | 1.06 (0.57–1.97) | ||
| Low risk(328) (REF) | 14.4 | |||||
| Exp. COVID-19 patients | Yes | 31.5 | ||||
| No (REF) | 11.1 | |||||
| Symptoms b | Any symptom | 52.4 | ||||
| No symptom (REF) | 9.8 | |||||
| CPI | Yes | 82.9 | ||||
| No (REF) | 15.1 | |||||
| Comorbidities | Yes | 19.4 | 0.84 | 1.07(0.56–2.02) | 0.319 | 0.65 (0.27–1.53) |
| No (REF) | 18.4% | |||||
Notes: Constant: −2.85 (p < 0.001); bAmong fever. cough, and shortness of breath. The statistically significant in the univariate and multivariate analysis is highlighted in bold.
Abbreviations: S, students; PASS, Physical Activity and Sports Sciences; TRS, teaching and research staff; Fis, Fisioterapy; AO, administrative officers; CPI, Confirmed previous infection; REF, reference; Exp. COVID-19 patients, Exposure to someone with COVID-19 patients.
Commorbidities of 705 Participants in the Faculty of Medicine and Health Sciences of the University of Alcalá, Madrid, Spain
| Diab | CD | PD | ID | P | RD | Ob | CORT | ARBs | ACE | Comorb | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 (0.4) | 3 (0.6) | 6 (1.2) | 2 (0.4) | 0 | 0 | 1 (0.2) | 3 (0.6) | 0 (0) | 1 (0.2) | 15 (3) | |
| 3 (2.3) | 25 (18.9) | 4 (3) | 0 | 2 (1.5) | 0 | 2 (1.5) | 5 (3.8) | 9 (6.8) | 7 (5.3) | 35 (26.5) | |
| 1 (1.5) | 14 (21.2) | 2 (3) | 0 | 0 | 1 (1.5) | 3 (4.5) | 1 (1.5) | 3 (4.5) | 5 (7.6) | 17 (25.8) | |
| p | 0.093 | <0.001 | 0.234 | 0.676 | 0.013 | 0.008 | 0.001 | 0.014 | <0.001 | <0.001 | <0.001 |
Abbreviations: CD, Cerebrovascular diseases; PD, Pulmonary disease; ID, Immunodeficiency; AC, Active Cancer; P, Pregnancy; LD, Liver Disease; RD, Renal Disease; Ob, Obesity; CORT, Corticosteroids; ARBs, Angiotensin receptor blockers; ACE, Angiotensin-converting enzyme inhibitors; Comorb, Comorbidities; S, Students; TRS, teaching and research staff; AO, administrative officers.
Figure 1Serological profile follow-up over time. Samples from participants with IgG-positive serum at first blood sampling (IgG June) were reassessed with serum obtained 23 weeks later (IgG November). Whisker-plots summarizing test values for both tests (IgG June and IgG November). Paired-Samplets T-Test. Mean (SD) are shown in June: 8.84(5.25) and November: 5.93: (4.24), Median and interquartile range are respectively: 7.7 (IQR:4.6–12.7) and 4.4 (IQR:2.8–8.0).